DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21-572/S-055

SUPPLEMENT APPROVAL

Cubist Pharmaceuticals, LLC c/o Merck Sharp & Dohme Corp.
Attention: Sandra Lynn Wood, PhD
Director, Global Regulatory Affairs
351 North Sumneytown Pike
P.O. Box 1000, Mailstop UG-2C48
North Wales, PA 19454-2505

Dear Dr. Wood:

Please refer to your Supplemental New Drug Application (sNDA) dated June 30, 2016, received June 30, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cubicin (daptomycin for injection) 500 mg/vial.

We also acknowledge receipt of your major amendment dated December 15, 2016, which extended the goal date by three months.

This Prior Approval supplemental new drug application provides for labeling changes regarding the use of daptomycin in the pediatric population for complicated skin and skin structure infections (cSSSI), based on the results of a trial in pediatric patients 1 to 17 years of age with cSSSI. This trial was conducted to fulfill the following Postmarketing Requirement listed in our February 11, 2015, letter:

- **2864-1:** Conduct a multicenter, evaluator blinded, randomized comparator study designed to assess the safety, efficacy, and PK of three age dependent doses of IV daptomycin administered for up to 14 days in pediatric patients aged *1 to 17 years*, inclusive with cSSSI caused by Gram-positive pathogens.

Specifically, the **DOSAGE AND ADMINISTRATION (2), ADVERSE REACTIONS (6), Clinical Trial Experience,** subsection **(6.1), USE IN SPECIAL POPULATIONS (8), and CLINICAL STUDIES (14)** sections of the U.S. package insert (PI) have been updated to reflect use in the pediatric population 1-17 years of age.

In addition, revisions have been made to the **DOSAGE AND ADMINISTRATION (2), Preparation and Administration of CUBICIN** subsection **(2.6)** of the PI to highlight the differences between Cubicin and Cubicin RF formulations regarding storage and reconstitution. Minor editorial revisions have also been made to different sections of the PI.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at:

http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm.

Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at:

http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

We acknowledge your March 28, 2017, submission containing final printed carton and container labels.

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels submitted on March 28, 2017, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).* Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 21-572/S-055**." Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURES: Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
03/29/2017